Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
Weitz JI, Segers A, Raskob G, Roberts RS, Francis C, Lassen MR, Fuji T, Swaim RM, Lee M, Peters G, DiBattiste PM, Tesfaye F, Strony J. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 12; 17(12):2081-2088.
-
Aged
-
Aged
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Humanized
-
Anticoagulants
-
Anticoagulants
-
Arthroplasty, Replacement, Knee
-
Arthroplasty, Replacement, Knee
-
Blood Coagulation
-
Blood Coagulation
-
Double-Blind Method
-
Double-Blind Method
-
Factor Xa Inhibitors
-
Factor Xa Inhibitors
-
Female
-
Female
-
Hemorrhage
-
Hemorrhage
-
Humans
-
Humans
-
Infusions, Intravenous
-
Infusions, Intravenous
-
Male
-
Male
-
Middle Aged
-
Middle Aged
-
Pyrazoles
-
Pyrazoles
-
Pyridones
-
Pyridones
-
Thrombin
-
Thrombin
-
Thrombin Time
-
Thrombin Time
-
Time Factors
-
Time Factors
-
Treatment Outcome
-
Treatment Outcome
-
Venous Thromboembolism
-
Venous Thromboembolism
-
Venous Thrombosis
-
Venous Thrombosis